{
    "id": 13377,
    "fullName": "ABL1 H396R",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ABL1 H396R lies within the protein kinase domain of the Abl1 protein (UniProt.org). H396R has been demonstrated to occur as a secondary drug resistance mutation in the context of BCR-ABL1 (PMID: 21562040, PMID: 28467002), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 3828,
                    "pubMedId": 21562040,
                    "title": "BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21562040"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11531,
                    "pubMedId": 28467002,
                    "title": "The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28467002"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 25,
        "geneSymbol": "ABL1",
        "terms": [
            "ABL1",
            "ABL",
            "BCR-ABL",
            "bcr/abl",
            "c-ABL",
            "c-ABL1",
            "CHDSKM",
            "JTK7",
            "p150",
            "v-abl"
        ]
    },
    "variant": "H396R",
    "createDate": "10/29/2015",
    "updateDate": "10/01/2019",
    "referenceTranscriptCoordinates": {
        "id": 119181,
        "transcript": "NM_005157",
        "gDna": "chr9:g.130874969A>G",
        "cDna": "c.1187A>G",
        "protein": "p.H396R",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 18697,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 H396R in the context of BCR-ABL1 demonstrated sensitivity to Bosulif (bosutinib) in culture, resulting in decreased cell viability (PMID: 25132497).",
            "molecularProfile": {
                "id": 22840,
                "profileName": "BCR - ABL1 ABL1 H396R"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18696,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ABL1 H396R in the context of BCR-ABL1 demonstrated sensitivity to Sprycel (dasatinib) in culture, resulting in decreased cell viability (PMID: 25132497).",
            "molecularProfile": {
                "id": 22840,
                "profileName": "BCR - ABL1 ABL1 H396R"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19144,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Asciminib (ABL001) inhibited proliferation of cells expressing BCR-ABL1 with ABL1 H396R in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 22840,
                "profileName": "BCR - ABL1 ABL1 H396R"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18695,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ABL1 H396R in the context of BCR-ABL1 demonstrated sensitivity to Tasigna (nilotinib) in culture, resulting in decreased cell viability (PMID: 25132497).",
            "molecularProfile": {
                "id": 22840,
                "profileName": "BCR - ABL1 ABL1 H396R"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18694,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ABL1 H396R in the context of BCR-ABL1 demonstrated sensitivity to Iclusig (ponatinib) in culture, resulting in decreased cell viability (PMID: 25132497).",
            "molecularProfile": {
                "id": 22840,
                "profileName": "BCR - ABL1 ABL1 H396R"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18693,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ABL1 H396R in the context of BCR-ABL1 demonstrated resistance to Gleevec (imatinib) in culture (PMID: 25132497).",
            "molecularProfile": {
                "id": 22840,
                "profileName": "BCR - ABL1 ABL1 H396R"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6256,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 20% (1/5) and major molecular response in 40% (2/5) of chronic myeloid leukemia patients harboring ABL1 H396R in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ABL1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 22840,
                "profileName": "BCR - ABL1 ABL1 H396R"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18698,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 H396R in the context of BCR-ABL1 demonstrated moderate resistance to Rebastinib (DCC-2036) in culture (PMID: 25132497).",
            "molecularProfile": {
                "id": 22840,
                "profileName": "BCR - ABL1 ABL1 H396R"
            },
            "therapy": {
                "id": 1045,
                "therapyName": "Rebastinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7978,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Iclusig (ponatinib) treatment did not result in clinical response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 H396R (88%), and H396R/V299L (5%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 23148,
                "profileName": "BCR - ABL1 ABL1 V299L ABL1 H396R"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7985,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment did not result in clinical response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 H396R/V299L (97%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 23148,
                "profileName": "BCR - ABL1 ABL1 V299L ABL1 H396R"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7984,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) resulted in a major molecular response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 F317L/H396R (75%), F317L/E279K (20%), F317L/E281K (2%), and F317L (1%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26127,
                "profileName": "BCR - ABL1 ABL1 E279K ABL1 E281K ABL1 F317L ABL1 H396R"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8337,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Tasigna (nilotinib) synergistically induced apoptosis in leukemia cells derived from Tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia patients harboring ABL1 H396R in the context of BCR-ABL1, and expressing Bcl2 in culture (PMID: 27605552).",
            "molecularProfile": {
                "id": 26234,
                "profileName": "BCR - ABL1 ABL1 H396R BCL2 pos"
            },
            "therapy": {
                "id": 4707,
                "therapyName": "Nilotinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6621,
                    "pubMedId": 27605552,
                    "title": "Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27605552"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18703,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 H396R and ABL1 T315I in the context of BCR-ABL1 demonstrated resistance to Bosulif (bosutinib) in culture (PMID: 25132497).",
            "molecularProfile": {
                "id": 33503,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 H396R"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18701,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 H396R and ABL1 T315I in the context of BCR-ABL1 demonstrated resistance to Gleevec (imatinib) in culture (PMID: 25132497).",
            "molecularProfile": {
                "id": 33503,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 H396R"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18702,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 H396R and ABL1 T315I in the context of BCR-ABL1 demonstrated resistance to Tasigna (nilotinib) in culture (PMID: 25132497).",
            "molecularProfile": {
                "id": 33503,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 H396R"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19198,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 H396R and T315I in the context of BCR-ABL1 demonstrated resistance to Asciminib (ABL001) in culture, and treatment with Asciminib (ABL001) did not provide a survival benefit over vehicle control in xenograft models (PMID: 31543464)",
            "molecularProfile": {
                "id": 33503,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 H396R"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20941,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Inlyta (axitinib) inhibited survival of transformed cells expressing both ABL1 T315I and ABL1 H396R in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 33503,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 H396R"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20955,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 H396R and T315I in the context of BCR-ABL1 were resistant to Iclusig (ponatinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 33503,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 H396R"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19203,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Asciminib (ABL001) to treatment with Iclusig (ponatinib) resulted in improved inhibition of proliferation compared to either agent alone in cells expressing ABL1 H396R and T315I in the context of BCR-ABL1 in culture, and improved survival and reduced tumor burden in xenograft models (PMID: 31543464).",
            "molecularProfile": {
                "id": 33503,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 H396R"
            },
            "therapy": {
                "id": 8935,
                "therapyName": "Asciminib + Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18704,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 H396R and ABL1 T315I in the context of BCR-ABL1 demonstrated resistance to Sprycel (dasatinib) in culture (PMID: 25132497).",
            "molecularProfile": {
                "id": 33503,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 H396R"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 13563,
            "profileName": "ABL1 H396R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22840,
            "profileName": "BCR - ABL1 ABL1 H396R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23148,
            "profileName": "BCR - ABL1 ABL1 V299L ABL1 H396R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23155,
            "profileName": "BCR - ABL1 ABL1 F317L ABL1 H396R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26127,
            "profileName": "BCR - ABL1 ABL1 E279K ABL1 E281K ABL1 F317L ABL1 H396R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26234,
            "profileName": "BCR - ABL1 ABL1 H396R BCL2 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33503,
            "profileName": "BCR - ABL1 ABL1 T315I ABL1 H396R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 119181,
            "transcript": "NM_005157",
            "gDna": "chr9:g.130874969A>G",
            "cDna": "c.1187A>G",
            "protein": "p.H396R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}